SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 24, 2026

ABCL

AbCellera Biologics Inc.
MIXED
Impact 5/10
Horizonweeks Processed2mo ago
Insider cluster: 2 insiders, $681K total
Actionable Insight ◆ Mixed

Director buying after a dilutive offering is a modestly bullish signal, but the small dollar amount relative to market cap limits conviction. Monitor for additional insider purchases or a catalyst event (e.g., ABCL635 data update) that could confirm the bullish read. The cross-filing context of the $200M offering remains the dominant near-term bearish factor.

DirectionMixed
Confidencemedium
Horizonweeks

ABCL635

● Neutral Named in this insider cluster
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$12.50
T+0 close · Aug 24, 2026 · via day close
Latest settled
−1.52%
T+20 · $12.31 · next T+60 tomorrow
Vs SPY
−1.77%
α at T+20
Latest observation
+17.58%
T+56 · FF3 residual α
  1. T+0 · Aug 25 $12.50entry
  2. T+1 · 3mo ago −2.08%α −2.10% · $12.24
  3. T+5 · 3mo ago −9.76%α −9.22% · $11.28
  4. T+20 · 8w ago −1.52%α −1.77% · $12.31
  5. T+58 · todayOpen
  6. T+60 · tomorrow Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two directors at AbCellera made open-market purchases totaling $681K, with the largest buy ($570K) occurring 13 days after a $200M dilutive offering. The insider buying follows a 93% bullish analyst consensus and positive Phase 2 data for ABCL635, but the capital raise creates a conflicting signal. Director purchases after a dilutive offering are unusual and may indicate confidence in the pipeline, though the cluster size is modest relative to the $3.3B market cap.

Key Financial Metrics

Direction
buying
Total Value
$681.0K
Insiders
2

Key Facts

  • Two directors purchased $681K in open-market transactions over a 7-day window
  • Largest buy: Director Michael R. Hayden purchased 53,613 shares at $10.64 for $570K
  • Purchases follow a $200M dilutive offering (424B5) filed 13 days prior on August 11, 2026
  • Total insider buying represents ~0.02% of the $3.3B market cap
  • 93% of analysts rate the stock as Buy or Strong Buy

Financial Impact

$681K in insider purchases, representing 0.02% of market cap

insider ownershipdilution

Risk Factors

  • Insider buying is small relative to market cap and may not signal broad confidence
  • The $200M dilutive offering overhangs the stock and could pressure near-term price
  • No C-suite participation in the buying cluster reduces signal strength

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ABCL-1787645044366

Track record

16 reports on ABCL

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Viewing Entry $12.50 Now $11.12 −11.04% settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026